Monitoring of intraventricularly administered vancomycin in infants in the treatment of ventriculitis

Authors

  • A BORONAT Departamento de Farmacia. Facultad de Química. General Flores 2124. Montevideo 11800, Uruguay.
  • M VÁZQUEZ Departamento de Farmacia. Facultad de Química. General Flores 2124. Montevideo 11800, Uruguay.
  • I OLANO Departamento de Farmacia. Facultad de Química. General Flores 2124. Montevideo 11800, Uruguay.
  • G COSTA Departamento de Neurocirugía. Instituto de Neurología. Facultad de Medicina. Hospital Universitario. Montevideo, Uruguay
  • A NEGROTTO Departamento de Neurocirugía. Instituto de Neurología. Facultad de Medicina. Hospital Universitario. Montevideo, Uruguay
  • P FAGIOLINO Departamento de Farmacia. Facultad de Química. General Flores 2124. Montevideo 11800, Uruguay.
  • E WILSON Departamento de Neurocirugía. Instituto de Neurología. Facultad de Medicina. Hospital Universitario. Montevideo, Uruguay

Keywords:

Vancomycin, cerebrospinal fluid, pharmacokinetics, ventriculitis

Abstract

The objective of this study was to establish guidelines for the monitoring of intraventricularly administeredVancomycin in infants.Eleven patients with ventriculo-peritoneal shunts who developed ventriculitis were included in the study.All patients were given an intraventricular (IVT) dose of Vancomycin. Cerebrospinal fluid (CSF)samples were analysed and pharmacokinetic parameters: elimination rate constant (ke) and distributionvolume (Vd) were calculated in order to adjust the dose. Mean values of Vd and elimination half-lifefor these patients were 244 (± 162) mL and 37.1 (±23.3) hours respectively.A great variability in the Vd was observed in some patients. This change in Vd correlates with problemsin the ventricle size or with septated ventricles. In all cases a new dose was suggested according to thecalculated parameters.Due to variations in the system throughout therapy, a protocol for CSF samples collection was proposedin order to individualise Vancomycin dosage according to pharmacokinetic parameters.

Downloads

Download data is not yet available.

References

Nau R, Sörgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998; 35: 223-246.

Chowdhury MH, Tunkel AR. Antibacterial agents in infections of the central nervous system. Infect Dis Clin North Am 2000; 14:391-408.

Mc Gee SM, Kaplan SL, Mason EO. Ventricular fluid concentrations of Vancomycin in children after intravenous and

intraventricular administration. Pediatr Infect Dis J 1990; 9: 138-139.

Schaad UB, Mc Cracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of Vancomycin in pediatrics patients. J Pediatr 1980; 96:119-126.

Luer MS, Hatton J .Vancomycin administration into cerebrospinal fluid: A review.Ann Pharmacother 1993; 27:912-921.

Rodvold KA, Everett JA, Pryka RD, Kraus DM. Pharmacokinetics and Administration regimens of Vancomycin in neonates, infants and children. Clin Pharmacokinet 1997; 33:32-51.

Bayston R, Hart CA, Barnicoat M. Intraventricular Vancomycin in the treatment of ventriculitis associated with cerebrospinal fluid shunting and drainage. J Neurol Neurosurg Psychiatry 1987; 50:1419-1423.

Ronat A, Geoffrey G. Cerebrospinal fluid shunt infections in children. Pediatric Infect Dis J. 1995; 14: 782-786.

Tomaszek DE, Powers SK. Treatment of Cerebrospinal fluid and Syringosubarachnoid shunt infection with systemic and

intrathecal antibiotics. Neurosurgery 1985; 17: 327-328.

Grabb PA, Albright AL. Intraventricular Vancomycin induced cerebrospinal fluid eosinophilia: Report of two patients.

Neurosurgery 1992; 30: 630-635.

Venkatesh B, Scott P, Ziegenfuss M. Cerebrospinal fluid in critical illness. Critical Care and Resuscitation 2000; 2: 42-54.

Lutsar I, Mc Cracken GH, Friedland RI. Antibiotic Pharmacodymamics in cerebrospinal fluid. Clin Infect Dis 1998; 27:

-1129.

Downloads

Published

2005-06-16

How to Cite

1.
BORONAT A, VÁZQUEZ M, OLANO I, COSTA G, NEGROTTO A, FAGIOLINO P, WILSON E. Monitoring of intraventricularly administered vancomycin in infants in the treatment of ventriculitis. Ars Pharm [Internet]. 2005 Jun. 16 [cited 2024 May 12];46(3):233-42. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/5076

Issue

Vol. 46 No. 3 (2005)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).